Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience

References

• World Health Organization. Pneumococcal vaccines. WHO position paper - 2012. Wkly Epidemiol Rec. 2012;87:129–144.
   PubMedGoogle Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines. 2009;8:1479–1500.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66–S76.
   PubMed Web of Science ®Google Scholar
• Knuf M, Pankow-Culot H, Grunert D, et al. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants. Pediatr Infect Dis J. 2012;31:e31–e36.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Coremans V, François N, et al. Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Expert Rev Vaccines. 2017;16:109–121.
   PubMed Web of Science ®Google Scholar
• Clarke C, Bakaletz LO, Ruiz-Guinazu J, et al. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines. 2017;16:1–14.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Valenciano M, Simondon F, et al. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31:5634–5642.
   PubMed Web of Science ®Google Scholar
• Leach AJ, Wigger C, Hare K, et al. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr. 2015;15:162.
   PubMed Web of Science ®Google Scholar
• Almeida SC, Cassiolato AP, Amorim CS, et al. Increase in 19A and 6C serotypes after 5 years of PCV10 routine immunization in Brazil. 10th International Symposium on Pneumococci and Pnemococcal Diseases; 2016 Jun 26-30; Glasgow, UK.
   Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214–222.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppä I, et al. Effectiveness of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media - a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5:237–248.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind, randomized controlled trial. PLoS Med. 2014;11:e1001657.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Ojal J, Bashraheil M, et al. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1–4 years: a randomized controlled trial. PLoS One. 2014;9:e85459.
   PubMed Web of Science ®Google Scholar
• Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29:1959–1967.
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30–e39.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. SIREVA II regional reports [internet]. Washington (DC): PAHO; 2012 [cited 2017 Nov 29]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=5536&Itemid=3966&lang=en
   Google Scholar
• Sartori AM, Nascimento Ade F, Yuba TY, et al. Methods and challenges for the health impact assessment of vaccination programs in Latin America. Rev Saude Publica. 2015;49:90.
   Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children - a population-based study. PLoS One. 2015;10:e0120290.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Palmu AA, Auranen K, et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36:1934–1940.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Auranen K, Palmu A, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) during ongoing national vaccination programme (NVP) in Finland. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Polkowska A, Toropainen M, Ollgren J, et al. Bacterial meningitis in Finland, 1995–2014: a population-based observational study. BMJ Open. 2017;7:e015080.
   PubMedGoogle Scholar
• Sihvonen R, Siira L, Toropainen M, et al. Streptococcus pneumoniae antimicrobial resistance decreased in the Helsinki Metropolitan Area after routine 10-valent pneumococcal conjugate vaccination of infants in Finland. Eur J Clin Microbiol Infect Dis. 2017;36:2109–2116.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471.
   PubMed Web of Science ®Google Scholar
• Verani JR, Domingues CM, Moraes JC. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33:6145–6148.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Minamisava R, Policena G, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Hum Vaccin Immunother. 2016;12:285–292.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Camacho LA, Coutinho ES, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: A systematic review. PLoS One. 2016;11:e0166736.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Almeida SCG, Minamisava R, et al. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36:2559–2566.
   PubMed Web of Science ®Google Scholar
• Erlendsdóttir H, Haraldsson A, Hrafnkelsson B, et al. An early reduction of invasive pneumococcal infections after PCV-10 immunisation. Poster session presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Kristinsson KG, Erlendsdóttir H, Quirk S, et al. Effect of pneumococcal vaccination on invasive pneumococcal disease in Iceland 2009–2015. Poster session presented at: 26th European Congress of Clinical Microbiology and Infectious Diseases; 2016 Apr 9–12; Amsterdam, The Netherlands.
   Google Scholar
• KEMRI Wellcome Trust. Pneumococcal conjugate vaccine impact study (PCVIS) [internet]. Kenya: KWTRP; 2017 [cited 2017 Nov 29]. Available from: http://kemri-wellcome.org/programme/pcvis-2/
   Google Scholar
• Nhantumbo AA, Weldegebriel G, Katsande R, et al. Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013–2015. PLoS One. 2017;12:e0177746.
   PubMed Web of Science ®Google Scholar
• Massora S, Mucavele H, Lessa F, et al. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease among children in Mozambique, 2008–2016. 11th International Symposium on Pneumococci and Pneumococcal Diseases 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32:1501–1506.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33:2684–2689.
   PubMed Web of Science ®Google Scholar
• Institute of Environmental Science & Research Limited. Public health surveillance information for New Zealand public health action - invasive pneumococcal disease reports [internet]. New Zealand: Ministry of Health; 2014 [cited 2017 Nov 29]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php
   Google Scholar
• Knol MJ, Wagenvoort GHJ, Sanders EAM, et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2015;21:2040–2044.
   PubMed Web of Science ®Google Scholar
• Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM). Pneumokokken [internet]. Amsterdam: RIVM; 2017 [cited 2017 Nov 29]. Available from: http://www.rivm.nl/Onderwerpen/P/Pneumokokken
   Google Scholar
• Knol MJ, Van der Ende A, Sanders L, et al. Vaccine effectiveness of 10-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: indirect cohort design. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26–30; Glasgow, UK.
   Google Scholar
• Naucler P, Galanis I, Morfeldt E, et al. Comparison of the impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017;65:1780–1789.
   PubMed Web of Science ®Google Scholar
• Schooley RT. Expression of concern relating to Naucler et al. Clin Infect Dis. 2018. DOI:10.1093/cid/ciy316
   Google Scholar
• GSK clinical study register: study numbers 113994, 116485 [internet]. UK: GSK;2017 [cited 2017 Nov 29]. Available from: https://www.gsk-clinicalstudyregister.com/files2/529cf371-82b1-40c4-9bed-2e116b36e6ac and https://www.gsk-clinicalstudyregister.com/files2/116485%20-%20Clinical-Study-Result-Summary.pdf
   Google Scholar
• Odutola A, Ota MC, Antonio M, et al. Immunogenicity and safety of an investigational protein-based pneumococcal vaccine in infants following 3+0 and 2+1 vaccination schedules: a phase II randomized trial in the Gambia. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016 Jun 26–30; Glasgow, UK.
   Google Scholar
• Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 2008;198:1818–1822.
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr., Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016–1027.
   PubMed Web of Science ®Google Scholar
• Synflorix, INN-Pneumococcal polysaccharide conjugate vaccine (adsorbed) [internet]. UK: European Medicines Agency; [ cited 2017 Nov 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf
   Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014;2:717–727.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Kilpi TM, Rinta-Kokko H, et al. Pneumococcal conjugate vaccine and clinically suspected invasive pneumococcal disease. Pediatrics. 2015;136:e22–e27.
   PubMed Web of Science ®Google Scholar
• Laaksonen N, Rintamäki L, Korppi M. Pneumococcal vaccinations effectively prevent blood culture-negative infections that resemble occult pneumococcal bacteraemia or bacteraemic pneumococcal pneumonia at one to 36 months of age. Acta Paediatr. 2016;105:1487–1492.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Klugman KP. World Health Organisation definition of “radiologically-confirmed pneumonia” may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine. 2007;25:2413–2419.
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810–815.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139–1146.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–1348.
   PubMed Web of Science ®Google Scholar
• Lucero MG, Nohynek H, Williams G, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J. 2009;28:455–462.
   PubMed Web of Science ®Google Scholar
• Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779–781.
   PubMed Web of Science ®Google Scholar
• Loens K, Van Heirstraeten L, Malhotra-Kumar S, et al. Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. J Clin Microbiol. 2009;47:21–31.
   PubMed Web of Science ®Google Scholar
• Kilpi T, Palmu AA, Puumalainen T, et al. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against hospital-diagnosed pneumonia in infants - FinIP trial. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2013 May 28–Jun 1; Milan, Italy.
   Google Scholar
• Kilpi T, Jokinen J, Puumalainen T, et al. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against radiologically confirmed pneumonia. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 Sep 5–9; Washington, DC.
   Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis. 2013;19:589–597.
   PubMed Web of Science ®Google Scholar
• Diaz J, Terrazas S, Bierrenbach AL, et al. Effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV-10) in children in Chile: A nested case-control study using nationwide pneumonia morbidity and mortality surveillance data. PLoS One. 2016;11:e0153141.
   PubMed Web of Science ®Google Scholar
• Fernández VJP, Goecke HC, von Borries C, et al. Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile. Rev Chil Pediatr. 2015;86:168–172. Spanish.
   PubMed Web of Science ®Google Scholar
• Minamisava R, Sgambatti S, Morais-Neto OL, et al. Impact of PCV10 introduction on pneumonia mortality rates in Brazil: a time series analysis. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Palmu AA, Rinta-Kokko H, Nohynek H, et al. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS One. 2017;12:e0172690.
   PubMed Web of Science ®Google Scholar
• Scotta MC, Veras TN, Klein PC, et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction. Vaccine. 2014;32:4495–4499.
   PubMed Web of Science ®Google Scholar
• Sgambatti S, Minamisava R, Bierrenbach AL, et al. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine. 2016;34:663–670.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Kristinsson KG, Erlendsdóttir H, et al. Decreased incidence of respiratory infections in children after vaccination with ten-valent pneumococcal vaccine. Pediatr Infect Dis J. 2015;34:1385–1390.
   PubMed Web of Science ®Google Scholar
• Silaba M, Ooko M, Bottomley C, et al. The impact of 10-valent pneumococcal conjugate vaccine (PCV10) on the incidence of radiologically-confirmed pneumonia and on pneumonia hospitalizations among children in Kilifi, Kenya. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26–30; Glasgow, UK.
   Google Scholar
• Verani J, Bigogo G, Muema S, et al. Pneumonia-related mortality among children in an urban slum in Nairobi, Kenya following 10-valent pneumococcal conjugate vaccine introduction. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26–30; Glasgow, UK.
   Google Scholar
• Andrade AL, Afonso ET, Minamisava R, et al. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis. PLoS One. 2017;12:e0184204.
   PubMed Web of Science ®Google Scholar
• Mucavele H, Massora S, Lessa F, et al. Impact of 10-valent pneumococcal conjugate vaccine on radiologically confirmed pneumonia among children in Mozambique 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• Zhou Z, Deceuninck G, Boucher F, et al. Impact of two pneumococcal conjugate vaccines on hospitalizations for lower-tract respiratory infections (LRTI) in Quebec, Canada. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Berglund A, Ekelund M, Fletcher MA, et al. All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. PLoS One. 2014;9:e112211.
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, Rowley S, Wong D, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and impact on nasopharyngeal carriage in Panamanian children - a randomized controlled trial. Human Vacc Immunother. 2017;13:1213–1228.
   PubMed Web of Science ®Google Scholar
• Qureishi A, Lee Y, Belfield K, et al. Update on otitis media - prevention and treatment. Infect Drug Resist. 2014;7:15–24.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Lancet Infect Dis. 2014;14:205–212.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Effectiveness of the ten-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial. Pediatr Infect Dis J. 2015;34:1230–1235.
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10–16.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23:732–738.
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367:740–748.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Rinta-Kokko H, Nohynek H, et al. Impact of national ten-valent pneumococcal conjugate vaccine programme on reducing antimicrobial use and tympanostomy tube placements in Finland. Pediatr Infect Dis J. 2018;37:97–102.
   PubMed Web of Science ®Google Scholar
• Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination; a national observational study. Pediatr Infect Dis J. 2017;36:1027–1031.
   PubMed Web of Science ®Google Scholar
• Talarico C, Feng Y, Medin E, et al. Impact of pneumococcal conjugate vaccines (PCVs) on otitis media incidence in Swedish children. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• Sigurdsson S, Eythorsson E, Hrafnkelsson B, et al. Reduction in all-cause acute otitis media in children less than three years of age in primary care following pneumococcal vaccination with PHiD-CV10: A whole population study. Clin Infect Dis. 2018. DOI:10.1093/cid/ciy233
   PubMed Web of Science ®Google Scholar
• Eyþorsson ES, Sigurdsson S, Hrafnkelsson B, et al. Pneumococcal vaccination in Iceland: PHiD-CV10 effectiveness against AOM associated antimicrobial prescriptions in children under three years of age. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• Rosenblut A, Rosenblut M, Garcia K, et al. Frequency of acute otitis media in children under 24 months of age before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the national immunization program in Chile. Pediatr Infect Dis J. 2018;37:132–134.
   PubMed Web of Science ®Google Scholar
• Sartori AL, Minamisava R, Bierrenbach AL, et al. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS One. 2017;12:e0179222.
   PubMed Web of Science ®Google Scholar
• De Wals P, Fratu R, Defay F, et al. Frequency of visits for otitis media in Quebec: face-to-nape comparison of children exposed to PCV-7 or PHiD-CV. 31st Meeting of the European Society for Paediatric Infectious Diseases; 2013 May 28–Jun 1; Milan, Italy.
   Google Scholar
• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154.
   PubMed Web of Science ®Google Scholar
• Adegbola RA, Deantonio R, Hill PC, et al. Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis. PLoS One. 2014;9:e103293.
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Käyhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11:841–855.
   PubMed Web of Science ®Google Scholar
• Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33(Suppl 2):S152–S160.
   PubMed Web of Science ®Google Scholar
• Kwambana-Adams B, Hanson B, Worwui A, et al. Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology. Sci Rep. 2017;7:8127.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Ternes YM, Vieira MA, et al. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One. 2014;9:e98128.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Zanella RC, Almeida SCG, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo, Brazil. Vaccine. 2016;34:5604–5611.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Erlendsdóttir H, Quirk SJ, et al. Pneumococcal vaccination: direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine. 2017;35:5242–5248.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2:e397–e405.
   PubMed Web of Science ®Google Scholar
• Neves FPG, Cardoso NT, Snyder RE, et al. Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: the emergence of multidrug resistant serotype 6C. Vaccine. 2017;35:2794–2800.
   PubMed Web of Science ®Google Scholar
• Neves FP, Pinto TC, Correa MA, et al. Nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among children from Brazil before the introduction of the 10-valent conjugate vaccine. BMC Infect Dis. 2013;13:318.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Toropainen M, Kaijalainen T, et al. Direct and indirect effectiveness of the 10-valent pneumococcal conjugate vaccine against carriage in a cluster randomized trial. Pediatr Infect Dis J. 2017;36:1193–1200.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population impact of 10-valent pneumococcal conjugate vaccine (PCV) on nasopharyngeal carriage of Streptococcus pneumoniae in Kilifi, Kenya. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33(Suppl 2):S161–S171.
   PubMed Web of Science ®Google Scholar
• Van Effelterre T, Moore MR, Fierens F, et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine. 2010;28:3650–3660.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Ruokokoski E, et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV10) on suspected non-confirmed invasive pneumococcal disease (IPD) in cluster-randomized trial. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Kilpi T, Palmu AA, Ruokokoski E, et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV10) on invasive pneumococcal disease (IPD) in a clinical trial. 8th World Congress of the World Society for Pediatric Infectious Diseases; 2013 Nov 19–22; Cape Town, South Africa.
   Google Scholar
• Palmu AA, Rinta-Kokko H, Nuorti JP, et al. A pneumococcal conjugate vaccination programme reduced clinically suspected invasive disease in unvaccinated children. Acta Paediatr. 2018. DOI:10.1111/apa.14335
   Web of Science ®Google Scholar
• Nuorti JP, Rinta-Kokko H, Toropainen M, et al. Invasive pneumococcal disease among adults after routine infant conjugate vaccination in Finland - implications for vaccination policy. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Caierão J, Cunha G, d’Azevedo PA, et al. Distribution of pneumococcal serotypes after introduction of 10-valent conjugate vaccine: a study involving adults with invasive disease, Porto Alegre, Brazil. 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11–15; Iguaçu Falls, Brazil.
   Google Scholar
• Azevedo J, Soares Santos M, Santos Galvão V, et al. The burden of invasive pneumococcal disease among older patients in the era of conjugate vaccine. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Lobo PR, Azevedo J, Silva E, et al. Epidemiology of pneumococcal meningitis in the metropolitan region of Salvador, Brazil, before and after the introduction of PCV10. Poster session presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; 2014 Mar 9–13; Hyderabad, India.
   Google Scholar
• Palmu A, Jokinen J, Puumalainen T, et al. Indirect impact of pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV10) on hospital-diagnosed pneumonia in cluster-randomized trial. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases; 2015 May 12–16; Leipzig, Germany.
   Google Scholar
• Okasha O, Rinta-Kokko H, Palmu AA, et al. Population-level impact of infant 10-valent pneumococcal conjugate vaccination on adult pneumonia hospitalisations in Finland. Thorax. 2018;73:262–269.
   PubMed Web of Science ®Google Scholar
• Vestjens SMT, Wagenvoort GHJ, Grutters JC, et al. Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands. Vaccine. 2017;35:4112–4118.
   PubMed Web of Science ®Google Scholar
• Monasta L, Ronfani L, Marchetti F, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012;7:e36226.
   PubMed Web of Science ®Google Scholar
• Izadnegahdar R, Cohen AL, Klugman KP, et al. Childhood Pneumonia in Developing Countries. Lancet Respir Med. 2013;1:574–584.
   PubMed Web of Science ®Google Scholar
• Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine. 2014;32:3133–3138.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine. 2018;36:1816–1822.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Houseman C, Hughes GJ, Chapman KE, et al. Increased invasive pneumococcal disease, North East England, UK. Emerg Infect Dis. 2017;23:122–126.
   PubMed Web of Science ®Google Scholar
• Vissers M, Wijmenga-Monsuur AJ, Knol MJ, et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS One. 2018;13:e0194823.
   PubMed Web of Science ®Google Scholar
• Hjálmarsdóttir MÁ, Quirk SJ, Sveinsdóttir H, et al. Pneumococcal vaccination in Iceland: the effect on antimicrobial susceptibility and serotype distribution. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19;Melbourne, Australia.
   Google Scholar
• Chauque A, Lessa F, Moiane B, et al. Declines in antimicrobial resistant (AMR)-Streptococcus pneumoniae after introduction of 10-valent pneumococcal conjugate vaccine (PCV10) in Mozambique. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15–19; Melbourne, Australia.
   Google Scholar
• Kim L, McGee L, Tomczyk S, et al. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29:525–552.
   PubMed Web of Science ®Google Scholar
• Shiragami M, Mizukami A, Leeuwenkamp O, et al. Reply to Farkouh RA et al. comment on “cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus Influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children”. Infect Dis Ther. 2015;4:235–244.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res. 2015;2015:591580.
   PubMed Web of Science ®Google Scholar
• Isturiz R, Sings HL, Hilton B, et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16:1007–1027.
   PubMed Web of Science ®Google Scholar
• Cohen O, Knoll M, O’Brien K, et al. Pneumococcal conjugate vaccine (PCV) product assessment. April 2017 [internet]. Baltimore: IVAC; 2017 [cited 2017 Nov 29]. Available from: https://www.jhsph.edu/research/centers-and-institutes/ivac/resources/pcv-product-assessment-april-25-2017.pdf.
   Google Scholar